Reuters logo
BRIEF-Morphosys, Galapagos start first-in-patient dosing of il-17c antibody MOR106
September 29, 2016 / 5:41 AM / a year ago

BRIEF-Morphosys, Galapagos start first-in-patient dosing of il-17c antibody MOR106

Sept 29 (Reuters) - Galapagos NV :

* Morphosys and Galapagos start first-in-patient dosing of il-17c antibody MOR106 in atopic dermatitis

* Ongoing phase 1 study in healthy volunteers now advanced to investigate MOR106 in patients with atopic dermatitis

* Favorable safety results shown in healthy volunteers receiving single ascending doses (SAD) in the study to date Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below